Work

Subclinical Cardiac Changes Following CPX‐351 Induction in Adults with Favorable/Intermediate‐Risk AML

Year: 2025

Type: article

Abstract: ABSTRACT CPX‐351 is associated with reduced non‐hematologic toxicity, but its cardiac safety is not well defined. We prospectively assessed ejection fraction (EF) and global longitudinal strain (GLS) in younger adults with AML treated with a single CPX‐351‐based induction. Median changes were mild and comparable to standard “7 + 3”. However, 27% developed clinically significant cardiac changes. These findings support prospective cardiac monitoring and the need for comparative studies. Trial Registration: NCT05599360

Source: eJHaem

DOI: 10.1002/jha2.70373